Chinese Association of Idaho State University (CAISU)
Structure of Human Amylin and Pramlintide
Structure of Human Amylin and Pramlintide
The most common adverse events associated with bromocriptine mesylate are nausea, fatigue, dizziness, vomiting and headache. Clinical trial data reveal that bromocriptine mesylate at doses up to 4.8 mg per day was not associated with a different rate of all-cause adverse events compared with placebo. However, the drug is known to be associated with nasal stuffiness, nausea, headache, constrictive pericarditis, neuroleptic malignant syndrome, and hypotension. The incidence of hypoglycemia was 6.9% among bromocriptine mesylate-treated patients compared with 5.3% of patients receiving placebo. In the pooled CYCLOSET phase 3 clinical trials (CYCLOSET N = 2298; placebo N = 1266) data, adverse events leading to discontinuation occurred in 539 (24%) CYCLOSET-treated patients and 118 (9%) placebo-treated patients. Pramlintide powder
This between-group difference was driven mostly by gastrointestinal adverse events, particularly nausea. This drug is contraindicated in patients with known hypersensitivity to bromocriptine or ergot-related drugs. It is also contraindicated in patients with syncopal migraine. Bromocriptine increases the likelihood of a hypotensive episode among patients with syncopal migraine. It is also contraindicated in nursing women as it may inhibit lactation.
There are post-marketing reports of stroke in these patients although causality has not been proven. • PRAMLINTIDE The hormone amylin ( Figure 12 ) is co-secreted with insulin by the pancreatic β cells in response to nutrient stimuli [268;269]. Patients with type 1 diabetes may develop an absolute deficiency of both insulin and amylin [270], and those with type 2 diabetes have impaired beta-cell secretion amylin in response to a meal. Amylin suppresses post-prandial arginine-stimulated glucagon secretion [272] and slows gastric emptying time [273]. Pramlintide® is a soluble synthetic analog of human amylin, allowing clinical application of this ...
The most common adverse events associated with bromocriptine mesylate are nausea, fatigue, dizziness, vomiting and headache. Clinical trial data reveal that bromocriptine mesylate at doses up to 4.8 mg per day was not associated with a different rate of all-cause adverse events compared with placebo. However, the drug is known to be associated with nasal stuffiness, nausea, headache, constrictive pericarditis, neuroleptic malignant syndrome, and hypotension. The incidence of hypoglycemia was 6.9% among bromocriptine mesylate-treated patients compared with 5.3% of patients receiving placebo. In the pooled CYCLOSET phase 3 clinical trials (CYCLOSET N = 2298; placebo N = 1266) data, adverse events leading to discontinuation occurred in 539 (24%) CYCLOSET-treated patients and 118 (9%) placebo-treated patients. Pramlintide powder
This between-group difference was driven mostly by gastrointestinal adverse events, particularly nausea. This drug is contraindicated in patients with known hypersensitivity to bromocriptine or ergot-related drugs. It is also contraindicated in patients with syncopal migraine. Bromocriptine increases the likelihood of a hypotensive episode among patients with syncopal migraine. It is also contraindicated in nursing women as it may inhibit lactation.
There are post-marketing reports of stroke in these patients although causality has not been proven. • PRAMLINTIDE The hormone amylin ( Figure 12 ) is co-secreted with insulin by the pancreatic β cells in response to nutrient stimuli [268;269]. Patients with type 1 diabetes may develop an absolute deficiency of both insulin and amylin [270], and those with type 2 diabetes have impaired beta-cell secretion amylin in response to a meal. Amylin suppresses post-prandial arginine-stimulated glucagon secretion [272] and slows gastric emptying time [273]. Pramlintide® is a soluble synthetic analog of human amylin, allowing clinical application of this ...
查看次数： 5
评论
您必须是爱达荷州立大学中国学生学者联谊会 的成员才能加评论！
加入 爱达荷州立大学中国学生学者联谊会